依奇珠单抗治疗重度银屑病的疗效及安全性分析  

Analysis of efficacy and safety of ixekizumab in the treatment of severe psoriasis

作　　者：郭洪飞[1] 马学良[1] 严旭[1] GUO Hong-fei;MA Xue-liang;YAN Xu(Department of Dermatology,Tengzhou Central People's Hospital,Tengzhou Shandong Province 277599,China)

机构地区：[1]滕州市中心人民医院皮肤科,山东滕州277599

出　　处：《中国城乡企业卫生》2024年第8期1-4,共4页Chinese Journal of Urban and Rural Enterprise Hygiene

摘　　要：目的探讨依奇珠单抗治疗重度银屑病的临床效果,为制订相关临床治疗方案提供参考。方法选取2019年10月—2020年5月滕州市中心人民医院收治的重度银屑病患者72例作为研究对象,随机分为对照组和研究组各36例。对照组给予常规药物治疗,研究组给予依奇珠单抗皮下注射治疗,两组均治疗6个月。比较两组炎性因子水平,T淋巴细胞、红细胞和中性粒细胞CKLF1表达,T淋巴细胞亚群,PASI评分及不良反应发生率。结果治疗6个月后,研究组IL-17、IL-1β、IL-6及TNF-α水平均低于对照组,差异均有统计学意义(P<0.05);研究组CKLF1在T淋巴细胞、红细胞和中性粒细胞中的表达比例均高于对照组,差异均有统计学意义(P<0.05);两组CD_(3)^(+)、CD_(4)^(+)、CD_(8)^(+)阳性细胞比例均较治疗前升高,CD_(4)^(+)/CD_(8)^(+)较治疗前降低,且研究组CD_(3)^(+)阳性细胞比例高于对照组,差异均有统计学意义(P<0.05)。治疗1、3和6个月,研究组PASI评分均低于对照组,差异均有统计学意义(P<0.05)。对照组和研究组不良反应发生率分别为22.22%和16.67%,差异无统计学意义(χ^(2)=0.355,P>0.05)。结论依奇珠单抗治疗重度银屑病疗效明显,可有效提高机体免疫和CKLF1表达,降低炎性因子、趋化因子水平,具有较好的安全性和耐受性。Objective To explore the clinical efficacy of ixekizumab in the treatment of severe psoriasis,in order to provide reference for the development of relevant clinical treatment plans.Methods A total of 72patients with severe psoriasis admitted to Tengzhou Central People's Hospital from October 2019 to May2020 were selected as the study subjects and randomly divided into control group and study group,with 36cases in each group.The control group received routine drug treatment,while the study group received subcutaneous injection treatment of ixekizumab.Both groups were treated for 6 months.The levels of inflammatory factors,the expression of CKLF1 in T lymphocytes,red blood cells and neutrophils,T lymphocyte subsets,PASI socres and the incidence of adverse reactions between two groups were compared.Results After 6 months of treatment,the levels of IL-17,IL-1β,IL-6 and TNF-αin the study group were lower than those in the control group,and the differences were statistically significant(P<0.05);the expression ratio of CKLF1 in T lymphocytes,red blood cells and neutrophils in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05);the proportion of CD_(3)^(+),CD_(4)^(+)and CD_(8)^(+)positive cells in both groups increased compared to before treatment,while CD_(4)^(+)/CD_(8)^(+)+decreased compared to before treatment,moreover,the proportion of CD_(3)^(+)positive cell in the study group was higher than that in the control group,and the differences were statistically significant(P<0.05).The PASI scores of the study group at 1,3 and 6 months of treatment were lower than those of the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the control group and the study group were 22.22%and 16.67%,respectively,and the difference was not statistically significant(χ^(2)=0.355,P>0.05).Conclusion Ixekizumab had a significant therapeutic effect in the treatment of severe psoriasis,which could effectively improv

关 键 词：依奇珠单抗 重度银屑病 趋化素样因子1 炎性因子 T淋巴细胞亚群 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]